DDInter1276 DDInter1628
Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Nelfinavir {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Nelfinavir {u} (Compound) upregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Nelfinavir {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Nelfinavir {u} (Compound) upregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is associated with {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Nelfinavir {u} (Compound) upregulates {v} (Gene) ACBD3
ACBD3 {u} (Gene) regulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Nelfinavir {u} (Compound) upregulates {v} (Gene) NUCB2
NUCB2 {u} (Gene) is downregulated by {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Nelfinavir {u} (Compound) upregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is regulated by {v} (Gene) PRKCE
PRKCE {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Nelfinavir {u} (Compound) upregulates {v} (Gene) ACBD3
ACBD3 {u} (Gene) regulates {v} (Gene) CDC45
CDC45 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Nelfinavir {u} (Compound) upregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) interacts with {v} (Gene) IRAK1
IRAK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Nelfinavir {u} may lead to a major life threatening interaction when taken with {v} Nilotinib
Nilotinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Nelfinavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Nelfinavir (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is upregulated by Ruxolitinib (Compound)
Nelfinavir (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Nelfinavir (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is associated with hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Nelfinavir (Compound) upregulates ACBD3 (Gene) and ACBD3 (Gene) regulates NFKBIA (Gene) and NFKBIA (Gene) is upregulated by Ruxolitinib (Compound)
Nelfinavir (Compound) upregulates NUCB2 (Gene) and NUCB2 (Gene) is downregulated by hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Nelfinavir (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is regulated by PRKCE (Gene) and PRKCE (Gene) is bound by Ruxolitinib (Compound)
Nelfinavir (Compound) upregulates ACBD3 (Gene) and ACBD3 (Gene) regulates CDC45 (Gene) and CDC45 (Gene) is downregulated by Ruxolitinib (Compound)
Nelfinavir (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) interacts with IRAK1 (Gene) and IRAK1 (Gene) is bound by Ruxolitinib (Compound)
Nelfinavir may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)